ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc (ENTA)

4.88
-0.15
( -2.98% )
Updated: 10:49:56

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
4.88
Bid
4.86
Ask
4.88
Volume
176,726
4.86 Day's Range 5.085
4.86 52 Week Range 17.80
Market Cap
Previous Close
5.03
Open
5.05
Last Trade
13
@
4.87
Last Trade Time
10:49:56
Financial Volume
US$ 871,280
VWAP
4.9301
Average Volume (3m)
449,435
Shares Outstanding
21,194,326
Dividend Yield
-
PE Ratio
-0.89
Earnings Per Share (EPS)
-5.48
Revenue
67.64M
Net Profit
-116.05M

About Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of... Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Enanta Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ENTA. The last closing price for Enanta Pharmaceuticals was US$5.03. Over the last year, Enanta Pharmaceuticals shares have traded in a share price range of US$ 4.86 to US$ 17.80.

Enanta Pharmaceuticals currently has 21,194,326 shares outstanding. The market capitalization of Enanta Pharmaceuticals is US$106.61 million. Enanta Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.89.

ENTA Latest News

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R...

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the...

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2 Demonstrated a...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.65-11.75406871615.535.684.868281155.14870089CS
4-1.37-21.926.256.454.867788425.65990907CS
12-7.7-61.208267090612.5813.36994.864494357.14127229CS
26-11.32-69.876543209916.217.2354.862951488.83494252CS
52-6.23-56.075607560811.1117.84.8625256310.79908927CS
156-55.88-91.968400263360.7679.4954.8625089027.17907443CS
260-52.84-91.545391545457.721024.8621744335.61564045CS

ENTA - Frequently Asked Questions (FAQ)

What is the current Enanta Pharmaceuticals share price?
The current share price of Enanta Pharmaceuticals is US$ 4.88
How many Enanta Pharmaceuticals shares are in issue?
Enanta Pharmaceuticals has 21,194,326 shares in issue
What is the market cap of Enanta Pharmaceuticals?
The market capitalisation of Enanta Pharmaceuticals is USD 106.61M
What is the 1 year trading range for Enanta Pharmaceuticals share price?
Enanta Pharmaceuticals has traded in the range of US$ 4.86 to US$ 17.80 during the past year
What is the PE ratio of Enanta Pharmaceuticals?
The price to earnings ratio of Enanta Pharmaceuticals is -0.89
What is the cash to sales ratio of Enanta Pharmaceuticals?
The cash to sales ratio of Enanta Pharmaceuticals is 1.53
What is the reporting currency for Enanta Pharmaceuticals?
Enanta Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Enanta Pharmaceuticals?
The latest annual turnover of Enanta Pharmaceuticals is USD 67.64M
What is the latest annual profit for Enanta Pharmaceuticals?
The latest annual profit of Enanta Pharmaceuticals is USD -116.05M
What is the registered address of Enanta Pharmaceuticals?
The registered address for Enanta Pharmaceuticals is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Enanta Pharmaceuticals website address?
The website address for Enanta Pharmaceuticals is www.enanta.com
Which industry sector does Enanta Pharmaceuticals operate in?
Enanta Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ERNAEterna Therapeutics Inc
US$ 0.7069
(128.77%)
468.28M
HEESH and E Equipment Services Inc
US$ 90.31
(105.53%)
8.31M
NMHINatures Miracle Holding Inc
US$ 2.3198
(105.29%)
143.77M
AIFFFirefly Neuroscience Inc
US$ 3.6442
(91.80%)
108.57M
SPISPI Energy Company Ltd
US$ 1.2611
(47.48%)
20.15M
PHIOPhio Pharmaceuticals Corporation
US$ 3.44
(-47.88%)
8.3M
MBIOMustang Bio Inc
US$ 0.1415
(-36.80%)
11.4M
SLRXSalarius Pharmaceuticals Inc
US$ 2.4871
(-32.23%)
1.38M
AVGRAvinger Inc
US$ 0.589
(-26.66%)
1.07M
AEHRAehr Test Systems
US$ 11.76
(-26.45%)
3.6M
ERNAEterna Therapeutics Inc
US$ 0.7021
(127.22%)
468.34M
RGTIRigetti Computing Inc
US$ 7.1688
(18.49%)
164.92M
NMHINatures Miracle Holding Inc
US$ 2.3199
(105.30%)
143.78M
AIFFFirefly Neuroscience Inc
US$ 3.6404
(91.60%)
108.61M
GCTKGlucoTrack Inc
US$ 0.1394
(-6.88%)
103.67M

ENTA Discussion

View Posts
biotech_researcher biotech_researcher 5 minutes ago
I violated my own covenant by buying ENTA in the $5.50 range. I normally always look at the insider ownership before I start a position. I failed to do this, and I paid the Ultimate investors choice. Insider ownership is pathetic. Most insiders own 30,000 shares or less. The CEO holds a total of 800,000 that's it. This is the latest information I have.
👍️0
vinmantoo vinmantoo 13 hours ago
Whether RFK is confirmed or not (I believe he and most of the nominees will be),

Given the lack of qualifications and low character, I sure hope most of the nominees are rejected.

I think it might be wise to anticipate a high degree of chaos from the incoming administration, which translates as volatility in the stock market.

Fully agree. I sold off half of my remaining RVNC and half of CDMO to generate a bigger cash cushion.
👍️ 1
Fred Kadiddlehopper Fred Kadiddlehopper 15 hours ago
Whether RFK is confirmed or not (I believe he and most of the nominees will be), I think it might be wise to anticipate a high degree of chaos from the incoming administration, which translates as volatility in the stock market.
👍️0
DewDiligence DewDiligence 16 hours ago
I hope that Kennedy is blocked from confirmation and I concur that it would be bullish for the biotech sector; however, I reject the notion that this is hugely consequential matter for ENTA one way or the other.
👍️ 3
biotech_researcher biotech_researcher 18 hours ago
If Kennedy is block, this will surge. We should know relatively soon..
👍️0
InefficientMarket InefficientMarket 18 hours ago
I added a little more today to push over 20k (excluding children) which is small potatoes compared rest of the Board. Anyone else notice that nearly every day for last two weeks the AH trades are higher than the Close. For example, i am seeing last trade at $5.23 with roughly 24,000 shares so far. Perhaps these trades are inaccurate because they are not actually AH -otherwise why would someone wait for extended trading/not use limit orders?
👍️0
alertmeipp alertmeipp 19 hours ago
Yes, some across the board short activities for sure. But from the few bio names I follow, none of them have 5x-6x average volumes last few weeks. That kind of volume spike is unique to ENTA.

It almost felt like they deliberately wanted to ensure we closed in the red. Every time ENTA had a run-up to breakeven during the day, a surge in volume would come in and push it down by a couple of percent.
👍️0
dewophile dewophile 19 hours ago
who the heck knows but my impression is because most bios fail and shorting across the board on average is a winning strategy some funds may do just that. In the meantime another down day (I can't remember the last time it was green) on 8x typical volume so same old same old
Maybe some folks who sold for tax reasons will buy later in the month since you have to wait a month for wash sale rules
👍️ 2
alertmeipp alertmeipp 20 hours ago
It actually requires a lot more conviction to hold a short position on a name that is trading less than cash value than to go long. Was thinking maybe some funds blow up, but even that won’t take this long to clear the inventory.
👍️0
dewophile dewophile 21 hours ago
it sure seems someone still wants out of a position or shorts are on the move, but it also must be the case that ENTA has become a trading name and you see the same shares changing hands multiple times a day, because otherwise it's hard to see the volume going from 100K a day to 500k+ day in day out
👍️ 3
dewophile dewophile 22 hours ago
GSK has a large respiratory and asthma business so this should be in their wheelhouse should they wish to pursue the immunology side of KIT
incidentally THRD is down 38% the last 2 trading days. I know bios have been pressured but this seems extreme. They are due to present phase 1 healthy volunteer data (along w biomarker data) this quarter. I see no news
👍️ 1
DewDiligence DewDiligence 1 day ago
Thanks. I may have stretched by pigeonholing the GSK deal as immunology, but it does bring the potential for GSK to expand into KIT immunology, as you noted.
👍️0
dewophile dewophile 1 day ago
GSK is in oncology but it is targeted to KIT and like BPMC they could segue to cKIT immunology down the road
GSK oncology after a terrible start has been a bit of a bright spot for the company. I sold most of my shares but still have a small position
👍️0
DewDiligence DewDiligence 1 day ago
Recent Immunology Deals Pertinent to ENTA (for_yellow_sticky)

GSK-IDRx
$1.15B cash buyout (incl $150M regulatory milestone)
MoA: KIT
Stage: phase-1b
Reference: #msg-175655362

GILD-Leo
Global collaboration: $250M up-front; $1.7B biobucks
MoA: STAT6
Stage: preclinical
Reference: #msg-175651641
👍️ 3
alertmeipp alertmeipp 1 day ago
Yes, disappointing, although I can see ENTA is trying to go UP today but the selling pressure persists. It is weird. I don’t even know which entities have so many shares readily available to sell after so much selling already
👍️0
dewophile dewophile 1 day ago
I miss the days when deals like this, JNJ etc would be good for a nice upward push in biotechs
The GILD deal on top of these right in ENTA's space would have been good for 10% plus - shows you how bad sentiment is right now
👍️ 3
DewDiligence DewDiligence 1 day ago
GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

• IDRX-42 offers potential to address all key KIT mutations in GIST that drive tumour growth and progression and improve tolerability…

Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. IDRX-42 is in phase-1/1b clinical development.
👍 1 👍️ 3
alertmeipp alertmeipp 2 days ago
Total is now 1.198 million shares. Pretty significant.

Top Institutional Holders
Farallon Capital Management LLC 2.11M Sep 30, 2024 9.95% 10,731,053
Vanguard Group Inc 1.98M Sep 30, 2024 9.35% 10,087,698
Blackrock Inc. 1.9M Sep 30, 2024 8.97% 9,672,644
Krensavage Asset Management, LLC 1.5M Sep 30, 2024 7.07% 7,625,196
This board
Morgan Stanley 1.1M Sep 30, 2024 5.20% 5,613,516
👍 4
biotech2020 biotech2020 2 days ago
108k shares here
👍️ 2
alertmeipp alertmeipp 3 days ago
Wow, I assume Leo’s stat6 program is much further along compared to ENTAs’? But it can’t be that far as they are still pre-clinical?

Why would Gilead pay so much upfront for it? I think dewophile quoted another similar deal, $150mm iirc, and also preclinical.

Maybe the next partnership news would be ENTA but on immunology instead of RSV. ;)
👍️ 2
alertmeipp alertmeipp 3 days ago
Total is now 1.09mm shares - slightly over 7 percent of the public float.

If we were a fund, we would be the 5th largest holder, on par with MS. We should have a say on ENTA future direction ;)
👍️ 2
vinmantoo vinmantoo 3 days ago
Between family accounts and the portfolio I manage for a private foundation, there are 360K shares.

Wow, with the numbers Alertmeipp has now gathered that means ~1 million shares from this people who use this board. I am just an Academic scientist who is relatively poor so my shares would be a rounding error so are not worth mentioning. You money bags guys can buy me a drink if ENTA does come back and hits big! 😁 🥂

After the long ENTA decline it represents ~10% or
👍️ 1
DewDiligence DewDiligence 3 days ago
GILD, Leo Pharma ink STAT6 collaboration:

https://www.businesswire.com/news/home/20250111983856/en Gilead Sciences…and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases.

…Targeting STAT6 has shown potential preclinically to treat a broad population of patients and provide an oral alternative to those currently treated with injectable biologics.

Under this partnership, Gilead will acquire LEO Pharma’s comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders. Gilead will lead further development efforts for the oral programs, while LEO Pharma will lead development for potential topical formulations of STAT6 inhibitors.

…Gilead will have global rights to develop, manufacture, and commercialize the small molecule oral STAT6 program. LEO Pharma will have the option to potentially co-commercialize oral programs for dermatology outside the United States. LEO Pharma will hold exclusive global rights to STAT6 topical formulations in dermatology.

LEO Pharma is eligible to receive up to $1.7 billion in total payments, including an upfront payment of $250 million. In addition, LEO Pharma may also receive tiered royalties ranging from high single-digit to mid-teens on sales of oral STAT6 products. Gilead may receive tiered royalties ranging from high single-digit to mid-teens on sales of topical STAT6 products.
👍️ 6
DewDiligence DewDiligence 3 days ago
Between family accounts and the portfolio I manage for a private foundation, there are 360K shares.
👍 3
tika1 tika1 3 days ago
10K here
👍️ 1
alertmeipp alertmeipp 3 days ago
Total now 720k - 4.67% of the public float (15.44mm) just from a few of us.
Interesting
(720370 shares).
👍️0
alertmeipp alertmeipp 3 days ago
considering more at this level.

The risk reward has been great since it traded below net cash value.. just couldn't imagine it can go this low.
👍 1
alertmeipp alertmeipp 3 days ago
>> down over $200k

Nice job actually, I would love to trade your cost basis with you any time. ;)
👍️ 2
mouton29 mouton29 3 days ago
I own 24,000.
👍️ 2
rwwine rwwine 3 days ago
33,200 shares and considering more at this level.
👍️ 2
LS89 LS89 3 days ago
129,770 and down over $200k
👍️ 2
alertmeipp alertmeipp 3 days ago
Enta is ripe for an activist investor

Won't be surprised at all if it happens. Could be easy money as long as they can ensure the company be rational on its RSV program.
👍️0
alertmeipp alertmeipp 4 days ago
Thanks, we have 555k total now.
👍️ 1
YY1000 YY1000 4 days ago
120k
👍️ 1
alertmeipp alertmeipp 4 days ago
FWIW - Another 250k plus traded after hours
👍️0
alertmeipp alertmeipp 4 days ago
I'm over 100k, so that's 2% of the float already.
Total is over 435k already.
👍️ 1
floblu14 floblu14 4 days ago
FLO = 100K

BABY FLO = .01
👍️ 2
wags23 wags23 4 days ago
I'm over 35k
👍️ 2
dewophile dewophile 4 days ago
I own 200k eom
👍️ 4 🙀 1
alertmeipp alertmeipp 4 days ago
I wonder how many shares this board own in total. Is there a way to do a tally in this board?
👍️0
alertmeipp alertmeipp 4 days ago
Some insider buys would be appreciated
👍️ 2
biotech_researcher biotech_researcher 4 days ago
Liquidation phase..
👍️0
dewophile dewophile 4 days ago
Enta is ripe for an activist investor
👍️ 3
vinmantoo vinmantoo 4 days ago
This is officially the ENTA theme song. "How low can you go"!

👍 1 👍️ 1 😂 2
wags23 wags23 4 days ago
Why would you want bad news?
👍️0
biotech_researcher biotech_researcher 4 days ago
The JPM conference can't come soon enough for ENTA..
👍️ 1
alertmeipp alertmeipp 5 days ago
Same. I guess that's the fun of small biotech investing. Out sized moves are the norm on both sides. Just hope we have some real news that would justify the 70% down move from $13 few short months ago.
👍️ 1
alertmeipp alertmeipp 5 days ago
No doubt, got lucky there. Hopefully here as well.
👍️0
dewophile dewophile 5 days ago
You lucked out on RVNC most lost money there - that is an example of a distressed buyout for sure. I have one example where I lost money despite a buyout and that was ZGEN. Sure I made back some paper losses, but net net was a loss. Can't win them all
👍️ 2
alertmeipp alertmeipp 5 days ago
There is no better feeling

Agree, hope we get to enjoy the feeling with ENTA soon. I made ok money with RVNC buyout offer and another one in energy sector recently. Both companies were undervalued with good quality assets and the assets would worth more under larger companies.

Not happen often but the feeling was awesome when it did indeed,

I probably have too much ENTA now, largest position by far. Started averaging down way too early unfortunately. Feel it is pretty safe to own as well, and with enough upside to compensate the wait time. But didn’t expect this to drop to this low. I thought net cash value would provide a solid good floor. But now we need to double just to get back to that. Live and learn I guess.
👍 1

Your Recent History

Delayed Upgrade Clock